All News

syringe,needle,vaccine

3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patients

Jack Cush, MD

ARD has publish a prospective, multicenter, observational study of vaccination outcomes in antineutrophil cytoplasmic antibodies associated vasculitis (AAV) patients, showing that AAV patients may not be adequately protected after standard two-dose COVID-19 vaccination, but that a third

Read Article
COVID Test Antibody

Weak Vaccine Responses in ANCA-Associated Vasculitis Patients

MedPage Today

Patients with ANCA-associated vasculitis (AAV) did not mount durable antibody responses to the SARS-CoV-2 Delta variant after the standard two-dose regimen of the Pfizer-BioNTech vaccine -- and for those taking rituximab (Rituxan) as maintenance therapy, even a third dose wasn't much help.

Read Article
RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Read Article
vaccine.jpg

Hold Myophenolate or Not with COVID-19 Vaccination?

Jack Cush, MD

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody responses than continuing MMF.

Read Article
COVID,vaccinate,injection,green

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Jack Cush, MD

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

Read Article
pregnancy,doctor,consult

COVID-19 in Pregnant Rheumatic Women

Jack Cush, MD

The Global Rheumatology Alliance (GRA) has studied the outcomes of women with rheumatic disease who were pregnant at the time of infection with coronavirus disease 2019 (COVID-19).

Read Article
ICYMI: JAMA reports that between Dec 2020 and July 2021, COVID-19 vaccination saved nearly 241,000 lives, prevented 1, 133, 617 hospitalizations and prevented more than 14 million COVID-19 cases (all in 1st 6 mos of the COVID vaccines) https://t.co/q9TvLjtY9p

Links:

Dr. John Cush RheumNow ( View Tweet)

3rd Vaccine Dose May Benefit ANCA-Associated Vasculitis Patients https://t.co/UXUryaQ7Fz https://t.co/p40xND4lVP

Links:

Dr. John Cush RheumNow ( View Tweet)
How's the United States doing on boosters? Trailing a long list of countries, including Serbia, Slovenia, and Lithuania @OurWorldInData https://t.co/cOCVoyuqT3
Eric Topol EricTopol ( View Tweet)
How Bad and How Far? CDC says to date, in the USA, there have been 6,715,937 COVID cases and 850,575 deaths from COVID-19. A total of 249,393,487 (75.1%) have recv at least one VAX dose, 209,312,770 (63%) fully VAX, 38.7% had a booster dose https://t.co/M9fYWL80ae

Links:

Dr. John Cush RheumNow ( View Tweet)

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients  https://t.co/dzDuza09JW https://t.co/HqL7nWdaP0

Links:

Dr. John Cush RheumNow ( View Tweet)
World Health Organization has recommended baricitinib & sotrovimab for COVID-19 (both already given EUA by the FDA). BARI (+/- steroids) given as 4 mg qd to severe hospitalized COVID. Sotrovimab, is for outpt, less severe disease. https://t.co/Hv8YdWUoYk https://t.co/l98zcyfGRk https://t.co/RAHKhqPWjp

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA reports that between Dec 2020 and July 2021, COVID-19 vaccination saved nearly 241,000 lives, prevented 1, 133, 617 hospitalizations and prevented more than 14 million COVID-19 cases (all in 1st 6 mos of the COVID vaccines) https://t.co/VIcwcPwbjn

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: JAMA study shows that, compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia (HR 0.83; 95% CI, 0.67-1.02; P = .08). https://t.co/72P5EHwD8l

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Patients on biologics are NOT at higher risk for COVID-19 infx. Retrospective matched cohort study compared 7631 Biologic Rx pts to 74910 matched cohort with equal Infx & death rates. COVID infx assoc w/ age, minorities, more comorbidities https://t.co/lY1MVpBoF1

Links:

Dr. John Cush RheumNow ( View Tweet)

Hold Myophenolate or Not with COVID-19 Vaccination? https://t.co/9Bp8huqJ6M https://t.co/AD11BmoZE8

Links:

Dr. John Cush RheumNow ( View Tweet)
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients  https://t.co/MrywKZKcIV https://t.co/QgajVPdesg

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA study shows that, compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia (HR 0.83; 95% CI, 0.67-1.02; P = .08). https://t.co/6dRd6gnkjc

Links:

Dr. John Cush RheumNow ( View Tweet)

Patients on biologics are NOT at higher risk for COVID-19 infx. Retrospective matched cohort study compared 7631 Biologic Rx pts to 74910 matched cohort with equal Infx & death rates. COVID infx assoc w/ age, minorities, more comorbidities https://t.co/GxmgWIbgSo

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Comorbidities Drive Risk of Severe Outcomes with COVID-19 https://t.co/9GgfvgnMke https://t.co/JGHp0mVPpF

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×